IPP Bureau
Solara’s Mangalore facility clears FDA inspection with VAI status
By IPP Bureau - November 23, 2025
Biocon Pharma gets FDA nod for arthritis drug Tofacitinib ER
By IPP Bureau - November 23, 2025
Tofacitinib extended-release tablets are a Janus kinase inhibitor indicated for Rheumatoid Arthritis
Croda partners with Amino to expand biopharma capabilities
By IPP Bureau - November 23, 2025
The partnership combines Croda’s deep expertise in smart science and global market reach with Amino’s advanced capabilities in precision manufacturing of amino acids
ACG unveils patent-clean laminate ‘DryPod’ to shake up moisture-protection market
By IPP Bureau - November 23, 2025
The company says the innovation delivers stronger moisture protection for highly sensitive drug molecules
Neurocrine review highlights key differences between tardive dyskinesia drugs
By IPP Bureau - November 23, 2025
Rafa Laboratories lands $186 million BARDA contract to develop life-saving trauma drug
By IPP Bureau - November 23, 2025
Landmark studies have shown that rapid TXA administration can significantly reduce mortality
FDA approves combo therapy for Cisplatin-ineligible muscle-invasive bladder cancer patients
By IPP Bureau - November 23, 2025
The approvals target adult MIBC patients who are ineligible for cisplatin-based chemotherapy
AstraZeneca to invest $2 billion in Maryland manufacturing expansion
By IPP Bureau - November 22, 2025
The multibillion-dollar Maryland expansion is part of AstraZeneca’s sweeping $50 billion global investment plan
Roche wins EU green light for one-minute injection cancer therapy
By IPP Bureau - November 22, 2025
FDA grants accelerated approval to sevabertinib for non-squamous non-small cell lung cancer
By IPP Bureau - November 21, 2025
HER2-mutant NSCLC typically has a poor prognosis and limited treatment options
Merck’s WINREVAIR shows promise in phase 2 study for hard-to-treat pulmonary hypertension
By IPP Bureau - November 21, 2025
The drug is being tested for combined post- and precapillary pulmonary hypertension due to heart failure with preserved ejection fraction
India’s Diabetes Crisis: Awareness and monitoring gaps threaten millions
By IPP Bureau - November 21, 2025
According to the ICMR-INDIAB study, 11.4% of adults in India have type 2 diabetes, while a staggering 15.3% are pre-diabetic
AbbVie’s EPKINLY gains FDA nod for relapsed follicular lymphoma, offering new hope for patients
By IPP Bureau - November 21, 2025
The full approval is based on the results from the pivotal Phase 3 EPCORE FL-1 study
BPL Medical Technologies brings next-gen Korean ultrasound to India
By IPP Bureau - November 21, 2025
The X CUBE 50 integrates ALPINION’s advanced X+ Architecture
Healthium Medtech to invest Rs. 150 crore in new Sri City facility, create 400 jobs
By IPP Bureau - November 21, 2025
